The Conference Forum has announced that the 3rd Annual Executing Global Clinical Trial’s event will take place on September 13-14 at the Fairmont Copley Square Hotel in Boston, MA. “The trend to globalization creates opportunities and challenges for clinical trial management. To be successful, we must focus on quality, ethics, fair market value, logistics and culture,” says Dr Barbara Skinn, Director of Collaborative Science Center of Excellence at Bristol-Myers Squibb.
Led by Dr Skinn along with Dr Mitchell Katz, Executive Director Medical Research Operations at Purdue Pharma and Dr Aleksander Skuban, Director, Clinical R&D Emerging Markets at Merck, the conference addresses the most critical issues in globalizing complex studies to make significant progress to advance drug development for the benefit of patients globally.
Dr Debra S. Barker, Chief Scientific Officer, Emerging Markets, Novartis and Dr Christopher Gallen, CEO, SK Bio-Pharmaceuticals are delivering the keynote addresses. David R. Jones, Expert Scientific Assessor (Pharmacotoxicologist), Licensing Division, Medicines and Healthcare Products Regulatory Agency (MHRA), UK is a featured presenter speaking on How to Do Clinical Trials in Europe: Clarifying Confusion, Changes & Updates.
As part of the conference, attendees will participate in region-specific round table discussions, including one-on-one question time with an industry expert in the following countries:
- Latin America
- Eastern Europe
Valerie Bowling, the Conference Director, commented, “Global clinical trial leaders universally requested we address the issues with the entire scope in mind to cover regulations, country-specific feasibility, infrastructure, training, support, diversity of locations, patients and culture, and we have developed the event specifically to do so.”
Participating companies include: Novartis; BBK Worldwide; CSL Behring; Endo; Strategic Clinical Research Consulting, LLC; Baxter Healthcare Corporation; SK Bio- Pharmaceuticals; Millenium Pharmaceuticals; Momenta Pharmaceuticals; Medicines and Healthcare Products Regulatory Agency (MHRA), UK; Purdue Pharma LP; EnVivo Pharmaceuticals, Inc; Target Health; AMAG Pharmaceuticals; Merck Brazil; Merck Research Laboratories; Bristol-Myers Squibb; AAHRPP; Marken and Zalicus.
For more information, please visit http://www.theconferenceforum.org
CONTACT: CIARA HEALY
PHONE: 646 350 2580 X310
The Conference Forum